Literature DB >> 12720483

Drug interactions of lithium and other antimanic/mood-stabilizing medications.

David L Dunner1.   

Abstract

Treatments for bipolar disorder often consist of a combination of 2 or more medications that have mood-stabilizing properties. Lithium is the only agent that has shown efficacy for the treatment of acute mania and acute depression as well as for the prevention of recurrence of mania and depression in patients with bipolar disorder. Other agents frequently used as mood stabilizers in monotherapy and in combination with lithium are valproate and carbamazepine. Several other drugs that have mood-stabilizing properties are used in many combinations to effectively manage the spectrum of symptoms of bipolar disorder throughout the acute and maintenance phases. However, side effects and drug-interaction precautions accompany all agents used to treat bipolar disorder, and often it can be difficult to determine whether a patient is suffering from side effects of treatment or symptoms of the illness itself. It is important to use the lowest effective dose of any treatment medication, to monitor laboratory values closely, and to be familiar with the side effects and interaction precautions of each medication that a patient is taking. Successful management of medications for the patient with bipolar disorder is a challenge, but increased effort and vigilance by clinicians mean a reduced risk of hospitalization and fewer office visits for patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720483

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

Review 1.  Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models.

Authors:  Gislaine Zilli Réus; Airam Barbosa de Moura; Laura Araújo Borba; Helena Mendes Abelaira; João Quevedo
Journal:  Mol Neuropsychiatry       Date:  2019-05-21

2.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

3.  Potentiation of Endocrine Adverse Effects of Lithium by Enalapril and Verapamil.

Authors:  R Krysiak; B Okopien
Journal:  West Indian Med J       Date:  2014-08-29       Impact factor: 0.171

4.  Aging changes and medical complexity in late-life bipolar disorder: emerging research findings that may help advance care.

Authors:  Martha Sajatovic; Brent P Forester; Ariel Gildengers; Benoit H Mulsant
Journal:  Neuropsychiatry (London)       Date:  2013-12-01

Review 5.  Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 6.  Clinical features, comorbidity, and cognitive impairment in elderly bipolar patients.

Authors:  Ida Vikan Rise; Josep Maria Haro; Bjørn Gjervan
Journal:  Neuropsychiatr Dis Treat       Date:  2016-05-17       Impact factor: 2.570

7.  The neuroprotective mechanism of lithium after ischaemic stroke.

Authors:  Beina Chen; Manman Zhang; Ming Ji; Dianjun Zhang; Binjie Chen; Wenliang Gong; Xinyu Li; Yuefei Zhou; Chengyi Dong; Gehua Wen; Xiaoni Zhan; Xiafang Wu; Huiya Yuan; Enyu Xu; Maosheng Xia; Alexei Verkhratsky; Baoman Li
Journal:  Commun Biol       Date:  2022-02-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.